FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies
IL-1 Trap Phase 3 Trial Data Presented at Annual Meeting of American Academy of Allergy, Asthma and Immunology (AAAAI)
March 15th, 2007
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that efficacy and safety data for the Phase 3 clinical trial of Regeneron's Interleukin-1 (IL-1) Trap (rilonacept) in patients with Cryopyrin-Associated Periodic Syndromes (CAPS) were presented at the 2007 American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting in San Diego, CA. The presentation was made by Dr. Hal Hoffman, Associate Professor of Pediatrics and Medicine, Division of Rheumatology, Allergy, and Immunology at the University of California at San Diego. This is the first presentation of the data at a scientific conference, having been accepted as a late-breaking abstract for the annual meeting....
Source: FDA Law Weekly (2007-03-15)
|
